Liu et al. (2021) revealed that the cisplatin treatment of non-small-cell lung cancer could be promoted by ADAM9 while being negatively regulated by miR-126-5p. Slapak et al. (2021) reported a novel ADAM9-responsive, protease-dependent, drug delivery system for patients with pancreatic ductal adenocarcinoma that can reduce the cytotoxicity of systemic chemotherapy. Here, ADAM9 is linked to non-small cell lung carcinoma.